ArticleNature immunology2025
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.
Abstract read
In one paragraph
Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies.bioRxiv : the preprint server for biology · 2026Article
- Diverse paths to broadly neutralizing antibody escape among HIV-1 strains.Nature microbiology · 2026Article
- HIV-1 BG505 SOSIP immunization induced B cell expansion targeting the 465-glycan hole, with neutralizing antibodies exhibiting distinct binding modes and mechanisms of virus inhibition.PLoS pathogens · 2026Article
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- Structural vaccinology expedites rational design of next-generation vaccines for influenza and respiratory syncytial virus.Virologica Sinica · 2026Review
- Clinical impact and cost-effectiveness of rapid versus non-rapid antiretroviral therapy initiation in HIV-positive men who have sex with men in China using modelling and 96-week multicenter cohort data.Scientific reports · 2026Article
- Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332Nature immunology · 2026Article
- Broadly neutralizing antibodies for treatment of HIV in children in the Global South: rationale and challenges.Frontiers in pediatrics · 2026Review
- Host restriction factors and p17-Driven inflammaging in HIV-1: From molecular pathogenesis to functional cure.AIMS microbiology · 2026Review
- Identification of a broad and potent V3 glycan site bNAb targeting an N332bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
49 authors.
Lutz Gieselmann *Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Andrew T DeLaitsch *Divison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0002-3458-3449
Malena RohdeLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Henning GruellLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-0725-7138
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0002-9140-9850
Meryem Seda ErcanogluLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Harry B GristickDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Philipp SchommersLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID http://orcid.org/0000-0003-3375-6800
Elvin AhmadovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Caelan RadfordBasic Sciences Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Andrea MazzoliniLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université and Université Paris-Cité, Paris, France.ORCID http://orcid.org/0000-0003-3194-2052
Lily ZhangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Anthony P WestDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0003-4213-5184
Johanna WorczinskiLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Anna AshurovLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Maren L ReichweinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jacqueline KnüferLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Ricarda StumpfLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Nonhlanhla N MkhizeSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0003-3037-1243
Haajira KaldineSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sinethemba BhebheSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Sharvari DeshpandeVir Biotechnology, San Francisco, CA, USA.
Federico GiovannoniVir Biotechnology, San Francisco, CA, USA.
Erin StefanuttiVir Biotechnology, San Francisco, CA, USA.
Fabio BenigniVir Biotechnology, San Francisco, CA, USA.
Colin Havenar-DaughtonVir Biotechnology, San Francisco, CA, USA.
Davide CortiVir Biotechnology, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-5797-1364
Arne KroidlInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.ORCID http://orcid.org/0000-0003-3569-9176
Anurag AdhikariDepartment of Infection and Immunology, Kathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.ORCID http://orcid.org/0000-0003-3168-0558
Aubin J NanfackChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Georgia E AmbadaChantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé, Cameroon.
Ralf DuerrDepartment of Microbiology, New York University School of Medicine, New York City, NY, USA.ORCID http://orcid.org/0000-0001-9569-9237
Lucas MagangaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Wiston WilliamMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Nyanda E NtinginyaMbeya Medical Research Centre, National Institute for Medical Research, Mbeya, Tanzania.
Timo WolfDepartment for Infectious Diseases, Centre of Internal Medicine II, University Hospital Frankfurt, Frankfurt am Main, Germany.
Christof GeldmacherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.
Michael HoelscherInstitute of Infectious Diseases and Tropical Medicine, LMU University Hospital, Munich, Germany.ORCID http://orcid.org/0000-0002-7642-1835
Clara LehmannGerman Center for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.
Penny L MooreSAMRC Antibody Immunity Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.ORCID http://orcid.org/0000-0001-8719-4028
Thierry MoraLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université and Université Paris-Cité, Paris, France.
Aleksandra M WalczakLaboratoire de Physique de l'Ecole Normale Supérieure, CNRS, Paris Sciences and Lettres University, Sorbonne Université and Université Paris-Cité, Paris, France.
Peter B GilbertVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nicole A Doria-RoseVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5731-3054
Yunda HuangVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Jesse D BloomBasic Sciences and Computational Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1267-3408
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Pamela J BjorkmanDivison of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0002-2277-3990
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. florian.klein@uk-koeln.de.ORCID http://orcid.org/0000-0003-1376-1792
Funding
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9MStuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MCHEETAH Center for the Structural Biology of HIV Infection, Restriction, and Viral DynamicsU54AI170856 · NIAID · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI WALTHER H MOTHES · 2022 to 2026
$34.4MDefining the mechanisms of HIV resistance to bNAbs in humansU01AI169385 · NIAID · ROCKEFELLER UNIVERSITY · PI Marina Caskey · 2022 to 2026
$7.8MComplete mapping of immune selection from antibodies to HIVR01AI140891 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BLOOM, JESSE D · 2019 to 2024
$2.4MAgence Nationale de la Recherche (French National Research Agency) ANR-19-CE45-0018Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) 1032144Gates Foundation INV-002143Gates Foundation INV-036842NIAID NIH HHS P01 AI100148NIAID NIH HHS R01 AI140891NIAID NIH HHS U01 AI169385NIAID NIH HHS U54 AI170856NIAID NIH HHS UM1 AI068635U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1U54AI170856U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) P01AI100148U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI140891U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U01AI169385
Abstract
Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection in vivo. However, clinical use is challenged by envelope diversity and rapid viral escape. Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies with highest antiviral activity. From 831 expressed monoclonal antibodies, we identified 04_A06, a V
Indexed as
Antibodies, NeutralizingCD4 AntigensHIV-1HIV AntibodiesHIV InfectionsAnimalsAntibodies, MonoclonalB-LymphocytesHIV Envelope Protein gp120HumansMiceAntibodies, MonoclonalAntibodies, NeutralizingCD4 AntigensHIV AntibodiesHIV Envelope Protein gp120
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.